Cardiology AdvisorACC Releases 2026 Expert Consensus Decision Pathway on HFpEF

✅ Guideline Update

The 2026 ACC expert consensus pathway updates practical guidance for diagnosing and managing HFpEF. The document emphasizes structured diagnostic assessment, exclusion of mimics, optimal medical therapy, nonpharmacologic care, and comorbidity management.

Clinical Considerations

• Diagnostic uncertainty remains central because no single test definitively establishes HFpEF.
• HFpEF scoring systems may support evaluation in patients with dyspnea, edema, or preserved ejection fraction.
• SGLT2 inhibitors and nonsteroidal MRAs anchor newer pharmacologic management discussions.
• CKM syndrome frames comorbidity management across obesity, diabetes, kidney disease, and cardiovascular risk.

Practice Applications

• Consider structured HFpEF scores during uncertain dyspnea evaluations.
• Recognize noncardiac and cardiac mimics before confirming HFpEF.
• Integrate CKM comorbidities into HFpEF treatment planning.
• Monitor therapy selection around contraindications, cost, and tolerance.